ZA200201225B - Diacylhydrazine derivatives. - Google Patents

Diacylhydrazine derivatives. Download PDF

Info

Publication number
ZA200201225B
ZA200201225B ZA200201225A ZA200201225A ZA200201225B ZA 200201225 B ZA200201225 B ZA 200201225B ZA 200201225 A ZA200201225 A ZA 200201225A ZA 200201225 A ZA200201225 A ZA 200201225A ZA 200201225 B ZA200201225 B ZA 200201225B
Authority
ZA
South Africa
Prior art keywords
formula
compounds
substance
solvates
physiologically acceptable
Prior art date
Application number
ZA200201225A
Other languages
English (en)
Inventor
Guenter Holzemann
Horst Kessler
Gabor Sulyok
Simon Goodman
Christoph Gibson
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ZA200201225B publication Critical patent/ZA200201225B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/06—Compounds containing any of the groups, e.g. semicarbazides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/18—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/02—Compounds containing any of the groups, e.g. carbazates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA200201225A 1999-07-14 2002-02-13 Diacylhydrazine derivatives. ZA200201225B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19932796A DE19932796A1 (de) 1999-07-14 1999-07-14 Diacylhydrazinderivate

Publications (1)

Publication Number Publication Date
ZA200201225B true ZA200201225B (en) 2003-07-30

Family

ID=7914676

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200201225A ZA200201225B (en) 1999-07-14 2002-02-13 Diacylhydrazine derivatives.

Country Status (24)

Country Link
US (1) US6649613B1 (pl)
EP (1) EP1194401B1 (pl)
JP (1) JP2003505365A (pl)
KR (1) KR20020022773A (pl)
CN (1) CN1210256C (pl)
AR (1) AR024741A1 (pl)
AT (1) ATE249427T1 (pl)
AU (1) AU762350B2 (pl)
BR (1) BR0012391A (pl)
CA (1) CA2379041A1 (pl)
CZ (1) CZ200219A3 (pl)
DE (2) DE19932796A1 (pl)
DK (1) DK1194401T3 (pl)
ES (1) ES2206275T3 (pl)
HK (1) HK1047085A1 (pl)
HU (1) HUP0202371A3 (pl)
MX (1) MXPA02000415A (pl)
NO (1) NO20020131L (pl)
PL (1) PL352966A1 (pl)
PT (1) PT1194401E (pl)
SI (1) SI1194401T1 (pl)
SK (1) SK192002A3 (pl)
WO (1) WO2001005753A1 (pl)
ZA (1) ZA200201225B (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10040105A1 (de) 2000-08-17 2002-02-28 Merck Patent Gmbh Peptid- und Peptidmimetika-Derivate mit Integrin-Inhibitor-Eigenschaften
DE10040103A1 (de) 2000-08-17 2002-02-28 Merck Patent Gmbh Peptid- und Peptidmimetika-Derivate mit Integrin-Inhibitor-Eigenschaften II
FR2828884B1 (fr) * 2001-08-27 2005-09-09 Centre Nat Rech Scient Hydrazinopeptoides et leurs utilisations dans le traitement des cancers
DE10209692A1 (de) * 2002-03-06 2003-09-18 Merck Patent Gmbh Isochinolinderivate
DE10325049A1 (de) * 2003-06-02 2004-12-23 Merck Patent Gmbh Peptid- und Peptidmimetika-Derivate mit Integrin-Inhibitor-Eigenschaften III
FR2859995A1 (fr) * 2003-09-23 2005-03-25 Centre Nat Rech Scient Hydrazinopeptoides reduits et leurs utilisations dans le traitement des cancers
PT1765362E (pt) 2004-06-04 2012-06-04 Scripps Research Inst Composições e métodos para o tratamento de doenças neovasculares
US20060126018A1 (en) * 2004-12-10 2006-06-15 Junzhong Liang Methods and apparatus for wavefront sensing of human eyes
MX2009012834A (es) 2007-05-29 2010-05-17 Intrexon Corp Ligandos quirales de diacilhidrazina para modular la expresion de genes exogenos por medio de un complejo receptor de ecdisona.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999020272A1 (en) * 1997-10-21 1999-04-29 Merck & Co., Inc. Azapeptide acids as cell adhesion inhibitors

Also Published As

Publication number Publication date
DE50003660D1 (de) 2003-10-16
KR20020022773A (ko) 2002-03-27
SI1194401T1 (en) 2004-02-29
WO2001005753A1 (de) 2001-01-25
NO20020131D0 (no) 2002-01-11
AU762350B2 (en) 2003-06-26
CN1360568A (zh) 2002-07-24
EP1194401A1 (de) 2002-04-10
HUP0202371A3 (en) 2002-11-28
BR0012391A (pt) 2002-03-19
ATE249427T1 (de) 2003-09-15
JP2003505365A (ja) 2003-02-12
CA2379041A1 (en) 2001-01-25
CZ200219A3 (cs) 2002-04-17
NO20020131L (no) 2002-03-12
DE19932796A1 (de) 2001-01-18
PL352966A1 (pl) 2003-09-22
ES2206275T3 (es) 2004-05-16
SK192002A3 (en) 2002-06-04
HK1047085A1 (zh) 2003-02-07
DK1194401T3 (da) 2004-08-16
CN1210256C (zh) 2005-07-13
EP1194401B1 (de) 2003-09-10
US6649613B1 (en) 2003-11-18
PT1194401E (pt) 2004-02-27
HUP0202371A2 (en) 2002-10-28
AU6155100A (en) 2001-02-05
AR024741A1 (es) 2002-10-23
MXPA02000415A (es) 2002-07-30

Similar Documents

Publication Publication Date Title
US6326403B1 (en) Diacylhydrazine derivatives as integrin inhibitors
US5935963A (en) Piperazinones, their production and use
US20030171304A1 (en) Pyridine-2-yl-aminoalkyl carbonyl glycyl-$g(b)-alanine and derivatives thereof
ZA200408027B (en) Isoquinoline derivatives.
US6649613B1 (en) Diacylhydrazine derivatives
JP2004524264A (ja) ビフェニル誘導体およびインテグリン阻害剤としてのその使用
RU2188205C2 (ru) Циклические азапептиды с ангиогенным действием
AU2004208865B2 (en) Peptidic sulfonamides
RU2200166C2 (ru) Производные циклопептидов в качестве ингибиторов адгезии
MXPA01000437A (en) Diacylhydrazine derivatives as integrin inhibitors
SK2952003A3 (en) Biphenyl derivatives and the use thereof as integrin inhibitors
CZ2001141A3 (cs) Derivát diacylhydrazinu jakožto integrinový inhibitor, způsob jeho přípravy, jeho použití a farmaceutický prostředek, který ho obsahuje